An editor and writer specialising in pharma, biotech and healthcare, Dominic Tyer is pharmaphorum's creative and editorial director and interim managing editor.
The UK could find its ability to counter the threat of a ‘super-gonorrhoea’ and other infectious diseases hampered if the country loses access to the EU’s early warning health system, the B
A bumper crop of orphan drugs from the likes of Amicus, Kyowa Kirin, Eusa and Biogen dominates this year’s UK Prix Galien shortlist as biotech firms and specialist pharma companies cement t
AstraZeneca has widened the licence for its cancer drug Tagrisso (osimertinib) in Europe after regulators gave it the green-light for first-line use against additional types of non-small ce
Merck & Co is working a major US hospital provider on a new software system that could help tackle the threat from healthcare-associated C. diff infections.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
